Vaccine For Influenza Articles & Analysis
23 news found
Creative Diagnostics' research team takes advantage of mouse models to study a variety of influenza A virus strains, including H9N2, H1N1 and H3N2. The portfolio offers customized and standard preclinical services to evaluate pathogenesis, humoral responses, and protective efficacy induced by wild-type influenza A viruses or influenza ...
Australian vaccine technology company BioDiem Ltd (“BioDiem”) announced that effective today, Mr Hugh Morgan AC, will step down from his non-executive director roles on the boards of BioDiem and its subsidiary, Opal Biosciences Ltd (“Opal”). ...
If VOLT elects not to exercise its option, Cancer Research UK will have the right to take the programme forward in all cancer indications. Unlike preventative vaccines, such as the influenza vaccine, which is given to healthy people to protect them against future disease, VTP-600 is given to people who already have lung cancer. ...
The World Health Organization (WHO) recently added COVAXIN™ (BBV152) to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using COVAXIN™ (BBV152). ...
The World Health Organization (WHO) recently added COVAXIN™ (BBV152) to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using COVAXIN™ (BBV152). ...
The World Health Organization (WHO) recently added COVAXIN™ to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using COVAXIN™. ...
The World Health Organization (WHO) recently added COVAXIN™ to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of COVID-19 vaccination certificates with India that includes vaccination using COVAXIN™. ...
David Hipkiss, Enesi Pharma CEO, commented: “ImplaVax® can reduce wastage, eliminate the need for cold-chain logistics, and allow for easier administration of vaccines – representing a potential paradigm shift in the deployment and reach of mass-immunisation programmes like those regularly undertaken for influenza. ...
(“Micron” or the “Company”), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical trial of its microneedle-based measles-rubella (“MR”) vaccine. ...
It potentially offers broad immunity against 100% of flu pandemics, 100% of animal influenzas and 80% of seasonal flu cases. The idea of a universal flu vaccine is not entirely novel. ...
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. Enesi Pharma (“Enesi”), an innovative ...
EnGen Bio is an early stage biotechnology company developing a new approach to preventing and treating all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global ...
Nowadays, access to modern therapeutics and seasonally effective vaccines reduces potential mortality posed by viral infection, and yet the current COVID-19 pandemic demonstrates humans’ continuing vulnerability to as-yet unidentified viral strains, especially from quickly mutating viruses such as influenza. ...
EnGen Bio is an early stage biotechnology company pioneering a new approach to preventing and treating influenza, with the goal of an effective, easy-to-manufacture, shelf-stable universal flu vaccine that should confer long-term immunity to all Type A influenza strains—including all flu pandemics. ...
Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines through its patented NanoVax™ adjuvant, today announced a ...
This second study consists of two different ARDS patient populations: one with COVID-19- mediated moderate to severe ARDS and the other with Influenza-mediated severe ARDS. AVM0703 is a novel and proprietary formulation of high concentration of dexamethasone. ...
(Micron) recently received a second tranche of funding ($2.6M) to continue clinical development of its microneedle-based technology for measles and rubella vaccination from the Bill & Melinda Gates Foundation. This work leverages Micron’s technology, which has already been successfully evaluated in clinical studies including a Phase 1 trial of an FDA-approved seasonal ...
Osivax, a clinical-stage biotech start’up focused on vaccines and based in Lyon (France), announces today the closing of a seed funding round of EUR 2.7 million. ...
This first scientific advice reinforces Imaxio’s plan to start, by early 2018, a phase I clinical trial involving IMX836. Imaxio’s influenza vaccine candidate IMX836 is being developed as an add-on to seasonal vaccines, in order to improve the effectiveness of prevention through vaccination, especially in elderly ...
Submitted in 2012 and 2013, and respectively entitled “Modified coiled-coil type proteins having improved properties” and “Influenza nucleoprotein vaccines”, these two patents offer additional cover on the American market to the new generation of Imaxio’s antigen re-engineering technology, as well as to its influenza ...